Skip to main content

Dexcom Value Stock - Dividend - Research Selection

Dexcom

ISIN: US2521311074, WKN: A0D9T1

Market price date: 21.09.2020
Market price: 391,69 USD




Dexcom Fundamental data and company key figures of the share

Annual reports in USD
Key figures 13-02-2020
Cash flow
Net operating cash flow 314.500.000
Capital Expenditures -180.000.000
Free cash flow 134.500.000
Balance sheet
Total Equity 882.600.000
Liabilities & Shareholders equity 2.395.000.000
Income statement
Net income 101.100.000
Eps (diluted) 1,100
Diluted shares outstanding 91.909.100
Net sales/revenue 1.476.000.000

Fundamental ratios calculated on: 21-09-2020

Ratios
Key figures 21-09-2020
Cash flow
P/C 114,47
   
P/FC 267,66
Balance sheet
ROI4,22
ROE36,85
Income statement
P/E356,08
Div. Yield0,00%
P/B40,79
P/S24,39


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolDXCM
Market Capitalization35.999.875.072,00 USD
CountryUnited States
IndicesNASDAQ 100,NASDAQ Comp.,NASDAQ 100,NASDAQ 100,S&P 500
Sectors
Raw Data SourceUS GAAP in Millionen USD
Stock Split
Internetwww.dexcom.com


Description of the company

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products; and a collaboration with Companion Medical, Inc. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.dexcom.com